TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.

ABSTRACT:

Objective

To evaluate the onset of efficacy of TEV-48125, a monoclonal antibody against calcitonin gene-related peptide, recently shown to be effective for the preventive treatment of chronic migraine (CM) and high-frequency episodic migraine.

Methods

A randomized placebo-controlled study tested once-monthly injections of TEV-48125 675/225 mg or 900 mg vs placebo. Headache information was captured daily using an electronic headache diary. The primary endpoint was change from baseline in the number of headache hours in month 3. Herein, we assess the efficacy of each dose at earlier time points.

Results

The sample consisted of 261 patients. For headache hours, the 675/225-mg dose separated from placebo on day 7 and the 900-mg dose separated from placebo after 3 days of

SUBMITTER: Bigal ME 

PROVIDER: S-EPMC4932236 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature